A "light" touch on PI3K to interrogate cancer drug resistance

Tianlu Wang; Yuepeng Ke; Yubin Zhou

doi:10.1016/j.chembiol.2022.11.005

A "light" touch on PI3K to interrogate cancer drug resistance

Cell Chem Biol. 2022 Nov 17;29(11):1573-1575. doi: 10.1016/j.chembiol.2022.11.005.

Authors

Tianlu Wang¹, Yuepeng Ke¹, Yubin Zhou²

Affiliations

¹ Center for Translational Cancer Research, Institute of Biosciences and Technology, Texas A&M University, Houston, TX 77030, USA.
² Center for Translational Cancer Research, Institute of Biosciences and Technology, Texas A&M University, Houston, TX 77030, USA; Department of Translational Medical Sciences, School of Medicine, Texas A&M University, Houston, TX 77030, USA. Electronic address: yubinzhou@tamu.edu.

Abstract

In this issue of Cell Chemical Biology, Ueda et al. (2022) developed PPAP2 as an improved optogenetic tool to photo-induce PI3K signaling hyperactivation in cancer cells. They demonstrated that enhanced translation of tumor necrosis factor alpha-induced protein 8 (TNFAIP8) might explain PI3K hyperactivation-associated resistance toward DNA damaging anti-cancer alkylating agents.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Antineoplastic Agents* / pharmacology
Antineoplastic Agents* / therapeutic use
Drug Resistance, Neoplasm
Humans
Light
Neoplasms* / drug therapy
Phosphatidylinositol 3-Kinases / metabolism
Signal Transduction

Substances

Antineoplastic Agents
Phosphatidylinositol 3-Kinases
TNFAIP8 protein, human

Grants and funding

R01 GM144986/GM/NIGMS NIH HHS/United States